Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France

References

• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels: Belgium International Diabetes Federation, 2013
   Google Scholar
• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
   PubMed Web of Science ®Google Scholar
• Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-15.
   PubMed Web of Science ®Google Scholar
• Webb DR, Khunti K, Gray LJ, et al. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med 2012;29:531-40
   PubMed Web of Science ®Google Scholar
• Sandbæk A1, Griffin SJ2, Sharp SJ2, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. Diabetes Care 2014;37:2015-23
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 2013;29:117-22
   PubMed Web of Science ®Google Scholar
• O'Reilly D, Gaebel K, Xie F, et al. Health economic evaluations help inform payers of the best use of scarce health care resources. Int J Circumpolar Health 2011;70:417-27
   PubMedGoogle Scholar
• Haute Autorité de santé. Choices in Methods for Economic Evaluation. Saint-Denis La Plaine: Haute Autorité de santé Communication Department, 2012. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf. Accessed August 28, 2014
   Google Scholar
• Davies MJ, Chubb BD, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med 2012;29:313-20
   PubMed Web of Science ®Google Scholar
• Mezquita Raya P, Pérez A, Ramírez de Arellano A, et al. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther 2013;4:417-30
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):27-40
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
   PubMed Web of Science ®Google Scholar
• van Dieren S1, Kengne AP, Chalmers J, et al. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Diabetes Obes Metab 2014;16:426-32.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Institut national de la statistique et des études économiques. Indices pour les revalorisations de pensions alimentaires. Paris: Institut mational de la statisique et des études éeconomiques, 2014. http://www.insee.fr/en/themes/conjoncture/serie_revalorisation.asp. Accessed August 28, 2014
   Google Scholar
• Allicar MP, Megas F, Houzard S, et al. Frequency and costs of hospital stays for hypoglycemia in France in 1995. Presse Med 2000;29:657-61
   PubMed Web of Science ®Google Scholar
• Sørensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int 2013;2013:Article ID 618039
   Google Scholar
• Beaudet A, Grabbi E, Maurel F, et al. Review of cost of diabetes complications in four European Countries. Value Health 2013;16:A443-4
   Google Scholar
• Gourdy P, Penfornis A, Charpentier G, et al. Effectiveness and tolerability with liraglutide among patients with type 2 diabetes – 2-year data from EVIDENCE: a prospective, follow-up, post-marketing study. Abstract presented at European Association for the Study of Diabetes annual meeting 2014, Vienna
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Zueger PM, Schultz NM, Lee TA. Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics 2014;32:1079-91
   PubMed Web of Science ®Google Scholar
• Lee WC, Samyshkin Y, Langer J, et al. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ 2015;15(2 Suppl):28-37
   Google Scholar
• Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012;28:436-44
   PubMed Web of Science ®Google Scholar
• Szende A, Oppe M, Devlin N, eds. EQ-5D Value sets: inventory, comparative review and user guide. Dordrecht, Netherlands: Springer, 2007
   Google Scholar
• Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ 2013;14:57-66
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Forti A, Chiasson J, et al. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycaemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial. Diabetes 2010;59(1 Suppl):A16 (58-OR)
   Google Scholar
• Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Malmenäs M, Bouchard JR, Langer J. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg. Clin Ther 2013;35:795-807
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Pawaskar M, Smith PJ, et al. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ 2012;15:1039-50
   PubMedGoogle Scholar
• Cobden DS, Niessen LW, Rutten FF, et al. Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach. Patient Prefer Adherence 2010;4:283-90
   PubMed Web of Science ®Google Scholar
• Raimond V, Josselin JM, Rochaix L. HTA agencies facing model biases: the case of type 2 diabetes. Pharmacoeconomics 2014;32:825-39
   PubMed Web of Science ®Google Scholar
• Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics 2014;32:15-27
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
   PubMed Web of Science ®Google Scholar